Prof Dr Els Van Nieuwenhuyzen presents the latest findings from the proffered paper session at ESMO23.
The FLAMES study, a phase 3 investigation involving randomized controlled patients afflicted with advanced ovarian cancer, unveiled the outcomes of administering senaparib after platinum chemotherapy. Senaparib was given over a two-year period or until the point of disease progression. Impressively, the study achieved its primary objective by demonstrating a 57% reduction in the risk of disease progression or death. Notably, this benefit was realized regardless of the patients’ BRCA mutation status. Furthermore, the study managed to diminish treatment-related toxicity without compromising the treatment’s efficacy.
In the ANITA trial, patients experiencing relapses in high-grade serous, endometrioid, or undifferentiated recurrent ovarian cancer after more than six months of platinum-based therapy were randomly assigned to receive atezolizumab or a placebo alongside platinum-based chemotherapy at a 1:1 ratio. Unfortunately, this study did not yield significant advantages for the primary endpoint of progression-free survival (PFS).
The phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trials investigated the incorporation of pembrolizumab into chemoradiotherapy for locally advanced cervical cancer. The participants in this study constituted a high-risk population, with 85% of them displaying node-positive lymph nodes. The primary endpoint was successfully met, indicating a 30% reduction in the risk of progression or death. Although overall survival (OS) data are still preliminary, they exhibit a similar promising trend. Importantly, the trial demonstrated a manageable safety profile, marking it as the first positive trial in locally advanced cervical cancer since the GOG120 study in 1999.
You may also be interested in:
With the educational support of:
 |
 |